Magnesium Sulfate (MgSO₄) — Mechanism of Action & Pharmacology

Chemistry & Ionic Basis

Magnesium (Mg²⁺) is the second most abundant intracellular cation. It is essential for the transport of Na⁺, Ca²⁺, and K⁺ across cell membranes, and most of its pharmacological actions stem from its ability to compete with calcium at key molecular targets. When administered as MgSO₄, the dissociated Mg²⁺ drives all the therapeutic effects.

Core Mechanisms of Action

1. Calcium Antagonism

The most unifying mechanism across all MgSO₄ uses is its role as a physiological calcium antagonist:

Mg²⁺ competes with Ca²⁺ for entry through voltage-gated and receptor-operated calcium channels
Elevated extracellular Mg²⁺ reduces intracellular Ca²⁺ in smooth muscle, myocardium, and neurons
This underlies its vasodilatory, tocolytic, bronchodilatory, and anticonvulsant effects

2. NMDA Receptor Antagonism

Mg²⁺ is a voltage-dependent blocker of the NMDA (N-methyl-D-aspartate) receptor channel pore
At resting membrane potentials, Mg²⁺ sits in the channel and physically blocks ion flux
This blocks calcium influx into neurons, reducing neuronal excitability
Proposed as a key mechanism for anticonvulsant action in eclampsia and neuroprotection in preterm neonates
- Bradley and Daroff's Neurology in Clinical Practice: "The anticonvulsant action may be mediated through magnesium sulfate's role as an NMDA antagonist"

3. Cardiac Conduction Effects

Slows the rate of SA node impulse formation
Prolongs conduction time through myocardial tissue
Restores transmembrane potential gradients via Na⁺/K⁺/Ca²⁺ transport
Drug of choice for torsades de pointes (polymorphic VT associated with long QT) and digoxin-induced arrhythmias
- Lippincott Illustrated Reviews: Pharmacology

4. Bronchodilation (Pulmonary)

Multiple mechanisms have been proposed (Fishman's Pulmonary Diseases):

Transient blockade of NMDA-gated calcium channels → ↓ intracellular Ca²⁺ in airway smooth muscle → relaxation
Inhibition of mast cell degranulation → ↓ histamine release
Inhibition of acetylcholine release from presynaptic terminals → reduced bronchoconstriction
Indicated in severe acute asthma (FEV₁ <30% predicted) not responding to initial therapy; the clinical benefit is present but modest
- Goodman & Gilman's Pharmacological Basis of Therapeutics: MgSO₄ reduces cytosolic Ca²⁺ concentrations in airway smooth muscle cells

5. Neuromuscular Effects

Competes with Ca²⁺ at the presynaptic terminal of the neuromuscular junction, reducing acetylcholine release
At toxic concentrations, causes progressive neuromuscular blockade (loss of deep tendon reflexes → flaccid paralysis)
This also explains its mild tocolytic effect on uterine smooth muscle (though its use as a standalone tocolytic is not recommended)

Serum Level–Dependent Effects

Serum Mg²⁺ Level	Effect
1.5–2.5 mEq/L	Normal range
>3 mg/dL	CNS depression
>5 mg/dL	↓ Deep tendon reflexes, flushing, somnolence
>12 mg/dL	Respiratory depression, cardiac arrest

Source: Harriet Lane Handbook, 23rd ed.

Antidote for Toxicity

Calcium gluconate (10 mL of 10% solution IV over 3 minutes) directly antagonizes Mg²⁺ toxicity by restoring normal Ca²⁺ levels and reversing respiratory depression. It should be kept at bedside whenever MgSO₄ is infused.

Summary Table of Clinical Uses by Mechanism

Clinical Use	Primary Mechanism
Eclampsia/preeclampsia	NMDA antagonism → anticonvulsant; cerebrovascular effect
Torsades de pointes	↓ SA automaticity; restores ion transport
Digoxin toxicity arrhythmias	Ca²⁺/membrane stabilization
Severe acute asthma	↓ airway smooth muscle Ca²⁺; mast cell inhibition
Neonatal neuroprotection (preterm <34 wk)	NMDA antagonism → reduces periventricular injury
Hypomagnesemia repletion	Direct electrolyte replacement

Key Sources:

Goodman & Gilman's The Pharmacological Basis of Therapeutics
Lippincott Illustrated Reviews: Pharmacology
Fishman's Pulmonary Diseases and Disorders
Bradley and Daroff's Neurology in Clinical Practice
Harriet Lane Handbook, 23rd ed.

This is a shared conversation. Sign in to Orris to start your own chat.